Hence, we reasoned that resistance to IMiD drugs in myeloma could be ascribed to reduced degradation of IKZF1 and IKZF3 as a result of inactivation of other essential components of the CRL4CRBN ligase complex, for instance the E2 ubiquitin conjugation enzyme. Here, UBE2E2 is linked to plasma cell myeloma.